In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae
- 1 June 1994
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 38 (6), 1402-1403
- https://doi.org/10.1128/aac.38.6.1402
Abstract
The in vitro susceptibilities of 12 strains of Chlamydia pneumonia to a new quinolone, OPC-17116; ofloxacin; and sparfloxacin were determined. OPC-17116 was slightly less active than sparfloxacin but more active than ofloxacin, with a MIC for 90% of strains tested and a minimal chlamydiacidal concentration for 90% of strains tested of 0.5 micrograms/ml.Keywords
This publication has 10 references indexed in Scilit:
- Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116Antimicrobial Agents and Chemotherapy, 1993
- The in-vitro activity of OPC-17116, a new 5-methyl substituted quinoloneJournal of Antimicrobial Chemotherapy, 1993
- In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1993
- In vitro activities of five quinolones against Chlamydia pneumoniaeAntimicrobial Agents and Chemotherapy, 1992
- In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116Antimicrobial Agents and Chemotherapy, 1992
- Persistent Infection with Chlamydia pneumoniae following Acute Respiratory IllnessClinical Infectious Diseases, 1992
- Infection with Chlamydia pneumoniae in BrooklynThe Journal of Infectious Diseases, 1991
- Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infectionsAmerican Journal Of Medicine, 1990
- A New Respiratory Tract Pathogen: Chlamydia pneumoniae Strain TWARThe Journal of Infectious Diseases, 1990
- In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolonesAntimicrobial Agents and Chemotherapy, 1988